← Leaderboards
Ann Petru
University Of California San Francisco
$791,951
Attributed
$791,951
Total exposure
18
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding mix
By agency
NIH$791,951 · 18
By mechanism
M01$791,951 · 18
Top collaborators
No co-investigators on record.
Most similar at University Of California San Francisco
Same institution · by research overlap
- Marcus Aaron Horwitz$40,522,782
- Laurence Huang$20,236,114
- Diane W. Wara$7,985,315
- Matthew G Dorsey$21,862,621
- Silvija I Staprans$7,069,069
Others in their field
Top investigators on “Clinical Research”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,040,569,537
- Leonard Freedman · Leidos Biomedical Research, Inc.$975,089,882
- Lawrence Corey · Fred Hutchinson Cancer Center$739,766,552
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Jeffrey P Krischer · University Of South Florida$611,867,176
- Barton F Haynes · Duke University$538,862,577
Research focus
Clinical ResearchHuman SubjectPediatric AidsHuman Therapy EvaluationAids TherapyCombination ChemotherapyHiv InfectionsDrug Screening /EvaluationClinical TrialsClinical Trial Phase IActive ImmunizationChild (0-11)Antiaids AgentZidovudineVirus LoadAids /Hiv NeuropathyInfant Human (0-1 Year)2'3'DideoxyinosineLamivudinePreschool Child (1-5)Adolescence (12-20)Longitudinal Human StudyBehavioral /Social Science Research TagHerpesviridae Vaccine
Grant awards (73)
LATE OUTCOMES FOR TREATMENT OF HIV INFECTION$273,187
M01 · FY2005 · RR
EFFECT OF ANTIRETROVIRAL THERAPY ON BODY COMPOSITION IN CHILDRENPACTG 1010$1,385
M01 · FY2005 · RR
ACTG P1024$1,385
M01 · FY2005 · RR
Late outcomes for treatment of HIV infection$214,103
M01 · FY2004 · RR
ACTG P1024 EVALUATION OF THE IMMUNOGENICITY OF PNEUMOCOCCAL CONJUGATE VACCINE...$12,570
M01 · FY2004 · RR
ACTG P1010 Effect of Antiretroviral Therapy on Body Composition in Children$3,530
M01 · FY2004 · RR
ACTG 265$1,229
M01 · FY2004 · RR
MEASLES VACCINE IN HIV INFECTED AND EXPOSED CHILDREN$0
M01 · FY2002 · RR
LATE OUTCOMES OF TREATMENT FOR HIV INFECTION$0
M01 · FY2002 · RR
3TC VERSUS THE BEST OF THERAPIES IN ACTG 152$0
M01 · FY2002 · RR
QUANTIFYING HIV 1 RNA IN CEREBROSPINAL FLUID &BLOOD$0
M01 · FY2002 · RR
VARICELLA VACCINE IN HIV INFECTED CHILDREN 12-48 MONTHS OLD$0
M01 · FY2002 · RR
ACTG 366: PATIENTS W/ RAPIDLY PROGRESSING ADVANCED DISEASE: "RAD-1"$0
M01 · FY2002 · RR
ZIDOVUDINE &LAMIVUDINE &NEVIRAPINE COMBINATION THERAPY IN HIV 1 INF$0
M01 · FY2002 · RR
PRAM 2--COMBINATION TREATMENT$0
M01 · FY2002 · RR
PRAM-NOVEL ANTIRETROVIRAL THERAPY IN STABLE, EXPERIENCED HIV INFECTED CHILDREN$0
M01 · FY2002 · RR
THERAPEUTIC TRIAL OF HIVIG IN CHILDREN WITH PROGRESSIVE DISEASE$0
M01 · FY2002 · RR
MOPPS MULTIPLE OPPORTUNISTIC PATHOGEN PREVENTION STUDY$0
M01 · FY2002 · RR
SAFETY &IMMUNOGENICITY OF A CONJUGATE PNEUMOCOCCAL VACCINE IN HIV INFANTS$0
M01 · FY2002 · RR
ZIDOVUDINE &LAMIVUDINE &NEVIRAPINE COMBINATION THERAPY IN HIV 1 INF$0
M01 · FY2001 · RR
PRAM-NOVEL ANTIRETROVIRAL THERAPY IN STABLE, EXPERIENCED HIV INFECTED CHILDREN$0
M01 · FY2001 · RR
3TC VERSUS THE BEST OF THERAPIES IN ACTG 152$0
M01 · FY2001 · RR
SAFETY &IMMUNOGENICITY OF A CONJUGATE PNEUMOCOCCAL VACCINE IN HIV INFANTS$0
M01 · FY2001 · RR
THERAPEUTIC TRIAL OF HIVIG IN CHILDREN WITH PROGRESSIVE DISEASE$0
M01 · FY2001 · RR
VARICELLA VACCINE IN HIV INFECTED CHILDREN 12-48 MONTHS OLD$0
M01 · FY2001 · RR
MOPPS MULTIPLE OPPORTUNISTIC PATHOGEN PREVENTION STUDY$0
M01 · FY2001 · RR
MEASLES VACCINE IN HIV INFECTED AND EXPOSED CHILDREN$0
M01 · FY2001 · RR
LATE OUTCOMES OF TREATMENT FOR HIV INFECTION$0
M01 · FY2001 · RR
QUANTIFYING HIV 1 RNA IN CEREBROSPINAL FLUID &BLOOD$0
M01 · FY2001 · RR
ACTG 366: PATIENTS W/ RAPIDLY PROGRESSING ADVANCED DISEASE: "RAD-1"$0
M01 · FY2001 · RR
PRAM 2--COMBINATION TREATMENT$0
M01 · FY2001 · RR
LATE OUTCOMES OF TREATMENT FOR HIV INFECTION$25,799
M01 · FY2000 · RR
MEASLES VACCINE IN HIV INFECTED AND EXPOSED CHILDREN$25,799
M01 · FY2000 · RR
MOPPS MULTIPLE OPPORTUNISTIC PATHOGEN PREVENTION STUDY$25,799
M01 · FY2000 · RR
VARICELLA VACCINE IN HIV INFECTED CHILDREN 12-48 MONTHS OLD$25,799
M01 · FY2000 · RR
THERAPEUTIC TRIAL OF HIVIG IN CHILDREN WITH PROGRESSIVE DISEASE$25,799
M01 · FY2000 · RR
SAFETY &IMMUNOGENICITY OF A CONJUGATE PNEUMOCOCCAL VACCINE IN HIV INFANTS$25,799
M01 · FY2000 · RR
3TC VERSUS THE BEST OF THERAPIES IN ACTG 152$25,799
M01 · FY2000 · RR
PRAM-NOVEL ANTIRETROVIRAL THERAPY IN STABLE, EXPERIENCED HIV INFECTED CHILDREN$25,799
M01 · FY2000 · RR
PRAM 2--COMBINATION TREATMENT$25,799
M01 · FY2000 · RR
ZIDOVUDINE &LAMIVUDINE &NEVIRAPINE COMBINATION THERAPY IN HIV 1 INF$17,457
M01 · FY2000 · RR
QUANTIFYING HIV 1 RNA IN CEREBROSPINAL FLUID &BLOOD$17,457
M01 · FY2000 · RR
ACTG 366: PATIENTS W/ RAPIDLY PROGRESSING ADVANCED DISEASE: "RAD-1"$17,457
M01 · FY2000 · RR
CAREGIVING &MENTAL HEALTH IN MOTHERS OF HIV+ CHILDREN$0
M01 · FY2000 · RR
CAREGIVING &MENTAL HEALTH IN MOTHERS OF HIV+ CHILDREN$0
M01 · FY2000 · RR
CAREGIVING &MENTAL HEALTH IN MOTHERS OF HIV+ CHILDREN$0
M01 · FY2000 · RR
QUANTIFYING HIV 1 RNA IN CEREBROSPINAL FLUID &BLOOD$0
M01 · FY2000 · RR
QUANTIFYING HIV 1 RNA IN CEREBROSPINAL FLUID &BLOOD$0
M01 · FY2000 · RR
ACTG 366: PATIENTS W/ RAPIDLY PROGRESSING ADVANCED DISEASE: "RAD-1"$0
M01 · FY2000 · RR
ACTG 366: PATIENTS W/ RAPIDLY PROGRESSING ADVANCED DISEASE: "RAD-1"$0
M01 · FY2000 · RR
ZIDOVUDINE &LAMIVUDINE &NEVIRAPINE COMBINATION THERAPY IN HIV 1 INF$0
M01 · FY2000 · RR
ZIDOVUDINE &LAMIVUDINE &NEVIRAPINE COMBINATION THERAPY IN HIV 1 INF$0
M01 · FY2000 · RR
PRAM 2--COMBINATION TREATMENT$0
M01 · FY2000 · RR
PRAM 2--COMBINATION TREATMENT$0
M01 · FY2000 · RR
PRAM-NOVEL ANTIRETROVIRAL THERAPY IN STABLE, EXPERIENCED HIV INFECTED CHILDREN$0
M01 · FY2000 · RR
PRAM-NOVEL ANTIRETROVIRAL THERAPY IN STABLE, EXPERIENCED HIV INFECTED CHILDREN$0
M01 · FY2000 · RR
3TC VERSUS THE BEST OF THERAPIES IN ACTG 152$0
M01 · FY2000 · RR
3TC VERSUS THE BEST OF THERAPIES IN ACTG 152$0
M01 · FY2000 · RR
SAFETY &IMMUNOGENICITY OF A CONJUGATE PNEUMOCOCCAL VACCINE IN HIV INFANTS$0
M01 · FY2000 · RR
SAFETY &IMMUNOGENICITY OF A CONJUGATE PNEUMOCOCCAL VACCINE IN HIV INFANTS$0
M01 · FY2000 · RR
THERAPEUTIC TRIAL OF HIVIG IN CHILDREN WITH PROGRESSIVE DISEASE$0
M01 · FY2000 · RR
THERAPEUTIC TRIAL OF HIVIG IN CHILDREN WITH PROGRESSIVE DISEASE$0
M01 · FY2000 · RR
VARICELLA VACCINE IN HIV INFECTED CHILDREN 12-48 MONTHS OLD$0
M01 · FY2000 · RR
VARICELLA VACCINE IN HIV INFECTED CHILDREN 12-48 MONTHS OLD$0
M01 · FY2000 · RR
MOPPS MULTIPLE OPPORTUNISTIC PATHOGEN PREVENTION STUDY$0
M01 · FY2000 · RR
MOPPS MULTIPLE OPPORTUNISTIC PATHOGEN PREVENTION STUDY$0
M01 · FY2000 · RR
MEASLES VACCINE IN HIV INFECTED AND EXPOSED CHILDREN$0
M01 · FY2000 · RR
MEASLES VACCINE IN HIV INFECTED AND EXPOSED CHILDREN$0
M01 · FY2000 · RR
LATE OUTCOMES OF TREATMENT FOR HIV INFECTION$0
M01 · FY2000 · RR
EFFECTS OF SCHOOL ENTRY ON HIV AFFECTED CHILDREN$0
M01 · FY2000 · RR
LATE OUTCOMES OF TREATMENT FOR HIV INFECTION$0
M01 · FY2000 · RR
EFFECTS OF SCHOOL ENTRY ON HIV AFFECTED CHILDREN$0
M01 · FY2000 · RR
EFFECTS OF SCHOOL ENTRY ON HIV AFFECTED CHILDREN$0
M01 · FY2000 · RR